Leiv Lea - 16 Mar 2022 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
Chief Financial Officer
Signature
/s/ Leiv Lea
Issuer symbol
CRVS
Transactions as of
16 Mar 2022
Net transactions value
+$77,045
Form type
4
Filing time
17 Mar 2022, 19:10:49 UTC
Previous filing
13 Sep 2021
Next filing
15 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRVS Common Stock Purchase $54,146 +35,160 +70% $1.54 85,360 16 Mar 2022 By IRA F1, F2
transaction CRVS Common Stock Purchase $22,899 +13,878 +16% $1.65 99,238 17 Mar 2022 By IRA F2, F3
holding CRVS Common Stock 149,206 16 Mar 2022 By Trust F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.45 to $1.60 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 These shares are held by Leiv Lea IRA Contributory.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.62 to $1.66 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 These shares are held by Leiv Lea and Deborah Karlson, Trustees of the Karlson Lea Family Trust UTA dated February 11, 1998 (the "Karlson Lea Trust"). Mr. Lea has shared voting, investment and dispositive power over the shares held by the Karlson Lea Trust.